Read by QxMD icon Read

Clinical and Experimental Rheumatology

Kathleen Morrisroe, Marie Hudson, Murray Baron, Jeska de Vries-Bouwstra, Patricia E Carreira, Dirk M Wuttge, Mianbo Wang, Tracy M Frech, Wendy Stevens, Susanna M Proudman, Mandana Nikpour
OBJECTIVES: To evaluate health-related quality of life (HRQoL) and its determinants in a systemic sclerosis (SSc) multinational inception cohort. We performed a meta-analysis of data from individual countries, and compared the meta-analysis to individual country results by pooling data from each of the countries. METHODS: SSc patients within 2 years of disease onset were recruited from 5 countries participating in the International Systemic Sclerosis Inception Cohort (INSYNC)...
August 31, 2018: Clinical and Experimental Rheumatology
Guoqin Q Wang, Yipu P Chen, Hong Cheng, Xiaoyi Y Xu, Lijun J Sun, Hongrui R Dong
OBJECTIVES: Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is an immune-mediated fibroinflammatory disorder and is characterised by elevated serum IgG4 concentrations and dense lymphoplasmacytic infiltrate rich in IgG4+ plasma cells. IgG4-related tubulointerstitial nephritis (IgG4-TIN) is the most common manifestation of IgG4-related kidney disease (IgG4-RKD). We report four cases of kidney injury with concurrent IgG4-TIN and crescentic glomerulonephritis confirmed by renal pathology...
August 29, 2018: Clinical and Experimental Rheumatology
Roberto Caporali, Daniela Zavaglia
OBJECTIVES: Oral targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs), including the Janus kinase inhibitors tofacitinib and baricitinib, are the latest addition to the therapeutic options for rheumatoid arthritis (RA). Tofacitinib 5 mg, twice daily, is approved for treatment, with or without methotrexate, of moderate to severe active RA in adults not adequately responding to, or not tolerating one or more DMARDs. In this narrative review we aimed to provide an overview of the real-world evidence for tofacitinib in RA...
August 29, 2018: Clinical and Experimental Rheumatology
José Mario Sabio, José Antonio Vargas-Hitos, Josefina Martínez Bordonado, Juan Diego Mediavilla-García
OBJECTIVES: Blood pressure (BP) physiologically declines more than 10% at night. Subjects who do not experience this drop are classified as non-dippers. They have a higher risk of cardiovascular diseases (CVD). Vitamin D deficiency and non-dipper pattern have been associated in the general population. Patients with systemic lupus erythematosus (SLE) are more likely to have vitamin D deficiency, a non-dipper pattern and CVD. We aimed to evaluate a possible relationship between vitamin D deficiency and non-dipper pattern in patients with SLE...
August 29, 2018: Clinical and Experimental Rheumatology
Christopher J Gasho, Karina D Torralba, David M Chooljian, Avi Cohen, Vi Am Dinh
OBJECTIVES: Lung ultrasound (LUS) plays an increasing role in diagnosis and monitoring of interstitial lung disease (ILD). Connective tissue disorders (CTD) frequently cause ILD, and often presents symptomatically after irreversible fibrosis has ensued. As point-of-care musculoskeletal ultrasound (US) is commonly utilised by rheumatologists, translating this US expertise towards LUS places the rheumatologist in a position to screen for ILD. However, a standardised curriculum for the rheumatology community is lacking...
August 29, 2018: Clinical and Experimental Rheumatology
Yanli Yuan, Xianhe Wang, Lijuan Ren, Yanliang Kong, Jie Bai, Yan Yan
OBJECTIVES: Interleukin-10 (IL-10) polymorphisms have been reported to be associated with systemic lupus erythematosus (SLE), however, the results are controversial. Therefore, we conducted a meta-analysis with trial sequential analysis to evaluate a more accurate estimation of the associations. METHODS: Eligible studies were retrieved by searching PubMed, Embase, Google Scholar, VIP, Wan Fang and China National Knowledge Infrastructure databases. Hardy-Weinberg equilibrium (HWE) was evaluated...
August 29, 2018: Clinical and Experimental Rheumatology
Claire E H Barber, Namneet Sandhu, James A Rankin, Paul MacMullan, Deborah A Marshall, Cheryl Barnabe, Glen S Hazlewood, Andrea Emrick, Martina Stevenson, Karen L Then, Susanne Benseler, Marinka Twilt, Dianne Mosher
OBJECTIVES: To develop a web-based tool (Rheum4U) to capture clinically meaningful data to direct treatment. Rheum4U integrates longitudinal clinical data capture of rheumatoid arthritis (RA) disease activity measures and patient-reported outcomes measures (PROMs). This study tests the feasibility, acceptability and efficiency of Rheum4U among patients and healthcare providers. METHODS: Rheum4U was developed in two phases: P1 design and development; and P2 pilot testing...
August 29, 2018: Clinical and Experimental Rheumatology
Muhammad K Nisar
OBJECTIVES: Acute gout is traditionally treated with NSAIDs, corticosteroids, and colchicine. However, the presence of comorbid conditions and advancing age, often seen in hospitalised patients, may prevent their use. We reviewed the published data on the use of ACTH in the treatment of acute gouty arthritis. METHODS: A search was performed up to June 2017. We included clinical trials or case studies/series where ACTH had been administered in human subjects as a treatment for acute gout or pseudogout...
August 29, 2018: Clinical and Experimental Rheumatology
Silvia Scriffignano, Fabio Massimo Perrotta, Antonia De Socio, Alessio Altobelli, Paola Sessa, Rossana Scrivo, Guido Valesini, Ennio Lubrano
OBJECTIVES: The aim of the present study was to validate an Italian version of the GRAPPA flare instrument to identify patients with psoriatic arthritis (PsA) with a possible disease flare. METHODS: This was a cross-sectional study enrolling consecutively PsA patients classified with CASPAR criteria. Inclusion criteria were: age ≥18 years and stable treatment (at least six months of follow-up) with conventional synthetic or biological DMARDs. The flare questionnaire was administered at baseline and within a two-week interval...
August 29, 2018: Clinical and Experimental Rheumatology
Massimiliano Vasile, Jerome Avouac, Iliana Sciarra, Katia Stefanantoni, Nicoletta Iannace, Elena Cravotto, Guido Valesini, Yannick Allanore, Valeria Riccieri
OBJECTIVES: Nailfold capillaroscopy (NC) shows microcirculatory abnormalities in systemic sclerosis (SSc). The inclusion of NC specific abnormalities increases the sensitivity of both 2013 ACR/EULAR and VEDOSS (Very Early Diagnosis of Systemic Sclerosis) classification criteria. We aimed to detect NC features able to predict progression toward established SSc in VEDOSS patients. METHODS: Sixty-six VEDOSS patients were enrolled. They had a clinical follow-up and underwent NC once a year, considering morphological parameters, appropriate pattern and semi- quantitative rating scale...
August 29, 2018: Clinical and Experimental Rheumatology
Tian-Ping Zhang, Yu-Lan Zhao, Xiao-Mei Li, Chang-Hao Wu, Hai-Feng Pan, Dong-Qing Ye
OBJECTIVES: Increasing studies have indicated the association between adipokines and multiple autoimmune diseases. This study aimed to evaluate the mRNA expression levels of vaspin, adiponectin and adrenomedullin in peripheral blood mononuclear cells (PBMCs) of patients with systemic lupus erythematosus (SLE), as well as their clinical associations. METHODS: A total of 46 SLE patients and 51 normal controls were recruited. The three adipokines expression levels in PBMCs from SLE patients were measured by qRT-PCR, and their associations with major clinical and laboratory parameters of SLE patients were also analysed...
August 29, 2018: Clinical and Experimental Rheumatology
Zhe Geng, Yikai Yu, Shaoxian Hu, Lingli Dong, Cong Ye
OBJECTIVES: The purpose of this study is to evaluate the relative risk (RR) of respiratory adverse events (AEs) among patients with RA treated with TCZ. METHODS: Databases (PubMed, Embase and Cochrane Library) were searched for randomised controlled trials (RCT) comparing the use of TCZ with placebo (PBO) or active comparator agents in adults with RA published until October 28, 2017. Statistical analyses were conducted to calculate the RR of infectious and non-infectious respiratory AEs and severe AEs (SAEs) using random-effects or fixed-effects models based on the heterogeneity of the included studies...
August 29, 2018: Clinical and Experimental Rheumatology
Alvise Martini, Vittorio Schweiger, Giovanna Del Balzo, Giulia Sartori, Massimo Parolini, Eris Chinellato, Piercarlo Sarzi-Puttini, Enrico Polati
Fibromyalgia's prevalence in Italy is about 4%. Apart from widespread pain and the three main conditions related to fibromyalgia that are included in its diagnosis (fatigue, unrefreshing sleep and cognitive disorders disturbances), there are a number of minor symptoms that have been associated to fibromyalgia. The current study aimed to characterise fibromyalgic patients referring to a single tertiary pain centre not only for sociodemographic data, but also with special attention on pharmacological history and "minor" symptoms...
August 29, 2018: Clinical and Experimental Rheumatology
Liqi Bi, Yuhui Li, Lan He, Huji Xu, Zhenyu Jiang, Yongfu Wang, Xiangpei Li, Wei Wei, Jieruo Gu, Guochun Wang, Zhiyi Zhang, Bin Zhou, Yi Liu, Zhenbiao Wu, Huaxiang Liu, Dongyi He, Zhaoping Lv, Zhijun Li, Xiaoxia Zuo, Lingli Dong, Huaxiang Wu, Hao Zhang, Haiying Chen, Chunde Bao, Zhuoli Zhang, Miaojia Zhang, Hui Song, Yi Zheng, Lindi Jiang, Xiangyuan Liu, Marion Boehnlein, Jochen Dunkel, Jing Shao, Kristina Harris, Zhanguo Li
OBJECTIVES: To evaluate the efficacy and safety of certolizumab pegol (CZP) in combination with methotrexate (MTX) in Chinese patients with active rheumatoid arthritis (RA) and an inadequate response to MTX. METHODS: This 24-week, phase 3, double-blind, placebo-controlled study was conducted in 30 centres across China. A total of 430 patients were randomised 3:1 to receive CZP 200 mg every 2 weeks (loading dose: 400 mg CZP at Weeks 0, 2 and 4) plus MTX or placebo (PBO) plus MTX...
August 29, 2018: Clinical and Experimental Rheumatology
Bhowmik Meghnathi, Pascal Claudepierre, Maxime Dougados, Anna Moltó
OBJECTIVES: To describe the prevalence of extreme patient-reported outcomes (PRO) in an early axial spondyloarthritis setting, to compare the phenotype of patients with/without extreme PRO and to evaluate the impact of extreme PRO on the effectiveness of TNF-α blockers (TNFb). METHODS: This analysis was performed in the DESIR cohort. Extreme PRO were measured at baseline and were defined as a score ≥8 on at least three of first five BASDAI items. Phenotype of patient's with/without extreme PRO was compared...
August 29, 2018: Clinical and Experimental Rheumatology
Antonio Marchesoni, Roberto Caporali, Ennio Lubrano
While the destructive changes of peripheral articular damage of psoriatic arthritis (PsA) are extensively studied, the productive modifications have been somewhat neglected. This literature-based study focuses on the clinically relevant aspects of peripheral bone proliferation in PsA. New bone proliferation frequently occurs as juxta-articular and entheseal apposition in PsA patients but also in psoriatic patients without arthritis, the Psoriatic Arthritis Ratingen Score is the only radiographic method to evaluate peri-articular new bone formation, numerous ultrasound systems to score entheseal changes have been proposed, several serum biomarkers of bone-turnover have been associated with PsA and psoriasis but they do not have clinical relevance...
August 29, 2018: Clinical and Experimental Rheumatology
Els Vandecasteele, Karin Melsens, Filip De Keyser, Michel De Pauw, Ellen Deschepper, Saskia Decuman, Yves Piette, Kristof Thevissen, Guy Brusselle, Vanessa Smith
OBJECTIVES: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading causes of death in systemic sclerosis (SSc). Although the six-minute walk test (6MWT) is used for evaluating ILD and PAH, no data are available on the evolution of the six-minute walk distance (6MWD) in SSc patients without ILD and PAH and whether the baseline 6MWD could serve as individual reference value for the management of those who will develop PAH or ILD. METHODS: Prospectively collected data of the first 6MWT (at baseline or 6-month follow-up) and the 6MWTs at 18-, 30-, 42-, 54-, and 66-month visit of 165 consecutive SSc patients without ILD and PAH, included in the Ghent University SSc Cohort between May 2006 and December 2016 were analysed...
August 28, 2018: Clinical and Experimental Rheumatology
Benjamin Korman, Rafael Alejo, Deepshika Sudhakar, Monique Hinchcliff, Rishi Agrawal, John Varga, Roberta G Marangoni
No abstract text is available yet for this article.
August 28, 2018: Clinical and Experimental Rheumatology
Antonella Fioravanti, Sara Tenti, Maria Romana Bacarelli, Arianna Damiani, Francesca Li Gobbi, Francesca Bandinelli, Sara Cheleschi, Mauro Galeazzi, Maurizio Benucci
OBJECTIVES: Adipokines play an important role in the pathophysiology of rheumatoid arthritis (RA), provide a link between the disease and overweight, contributing to explain the enhanced cardiovascular (CV) risk and influence the response to disease-modifying anti-rheumatic drugs. The aim of this study was to determine the possible effects of intravenous (IV) tocilizumab (TCZ), an interleukin-6 receptor antagonist, on serum levels of leptin, adiponectin, resistin, visfatin, and chemerin...
August 27, 2018: Clinical and Experimental Rheumatology
Maya H Buch, Alyssa Johnsen, Michael Schiff
OBJECTIVES: To explore antinuclear autoantibody (ANA) and anti-double-stranded DNA (anti-dsDNA) autoantibody development during abatacept and tumour necrosis factor inhibitor (TNFi) treatment, and effects of switching from TNFi to abatacept in ANA/anti-dsDNA autoantibody-positive patients. METHODS: This was a post hoc analysis of biologic-naïve patients with active RA in ATTEST and AMPLE. In AMPLE, patients received subcutaneous abatacept or adalimumab (2 years)...
August 21, 2018: Clinical and Experimental Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"